Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China
Portfolio Pulse from Vandana Singh
Novo Nordisk A/S (NVO) faces shortages of Ozempic starter kits in Germany due to high demand for its weight-reducing effects, with limited availability expected through 2024. Meanwhile, a Chinese company, Hangzhou Jiuyuan Gene Engineering, has developed a biosimilar, Jiyoutai, potentially challenging Ozempic's market in China. Eli Lilly And Co (LLY) also experiences tight supply of its diabetes drug Mounjaro until 2024 due to high demand.
April 03, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's diabetes drug Mounjaro faces tight supply until 2024 due to high demand, potentially impacting its market share and revenue.
Eli Lilly's Mounjaro facing supply issues until 2024 due to high demand indicates potential revenue impact and market share challenges. The tight supply could limit the drug's availability to patients, affecting sales and competitive positioning in the diabetes treatment market.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 70
NEGATIVE IMPACT
Novo Nordisk's Ozempic faces shortages in Germany and potential competition in China from a biosimilar, impacting its market dominance and revenue.
The shortages of Ozempic in Germany due to high demand, coupled with the introduction of a biosimilar in China, could negatively impact Novo Nordisk's revenue and market share in the short term. The situation is exacerbated by the company's inability to meet demand in Europe and the potential for increased competition in China.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90